Revisiting the Role of Intravitreal Triamcinolone in Diabetic Macular Edema: 12-Month Outcomes after Bevacizumab Failure
Repeated IVTA treatments for DME refractory to bevacizumab over a 12-month period demonstrated efficacy and appeared to have a comparable safety profile. Patients with thinner CMT before IVTA treatment had a greater probability of remaining DME-free after IVTA treatment.
Authors
- Variya Nganthavee (ORCID: https://orcid.org/0000-0001-7457-999X)
- Pawas Lalitwongsa
- Sukhum Silpa‐archa (ORCID: https://orcid.org/0000-0002-3903-1889)
- Peranut Chotcomwongse
- Paisan Ruamviboonsuk
Institutions
- Priest Hospital (TH)
- Rangsit University (TH)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2025-06-07
- DOI
- https://doi.org/10.1007/s40123-025-01172-5
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71